$116 Million is the total value of Lynx1 Capital Management LP's 13 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CABA | New | CABALETTA BIO INC | $26,140,278 | – | 2,825,976 | +100.0% | 22.61% | – |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $22,977,372 | +4.4% | 3,126,173 | +2.3% | 19.87% | +0.1% |
| MRUS | Buy | MERUS N V | $13,220,523 | +7.7% | 854,591 | +39.4% | 11.43% | +3.2% |
| KNTE | Buy | KINNATE BIOPHARMA INC | $12,190,344 | -39.1% | 1,998,417 | +19.3% | 10.54% | -41.6% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $10,367,414 | +27.4% | 1,653,495 | -28.9% | 8.97% | +22.1% |
| BLU | Sell | BELLUS HEALTH INC NEW | $8,991,858 | -64.3% | 1,093,900 | -54.1% | 7.78% | -65.7% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $5,853,728 | +44.8% | 5,628,585 | +60.1% | 5.06% | +38.8% |
| Buy | PARDES BIOSCIENCES INC | $5,075,242 | +20.6% | 3,003,102 | +32.0% | 4.39% | +15.6% | |
| PASG | Buy | PASSAGE BIO INC | $4,631,165 | +34.6% | 3,355,917 | +21.9% | 4.00% | +29.0% |
| Buy | THESEUS PHARMACEUTICALS INC | $3,905,107 | +33.4% | 784,158 | +55.3% | 3.38% | +27.9% | |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $1,166,187 | – | 2,291,133 | +100.0% | 1.01% | – |
| New | AADI BIOSCIENCE INC | $830,601 | – | 64,739 | +100.0% | 0.72% | – | |
| PHVS | New | PHARVARIS N V | $284,906 | – | 25,325 | +100.0% | 0.25% | – |
| OTIC | Exit | OTONOMY INC | $0 | – | -2,312,880 | -100.0% | -0.62% | – |
| IMUX | Exit | IMMUNIC INC | $0 | – | -1,072,288 | -100.0% | -3.06% | – |
| AVTE | Exit | AEROVATE THERAPEUTICS INC | $0 | – | -276,447 | -100.0% | -4.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.